James Jones - Cumberland Pharmaceuticals Independent Director
| CPIX Stock | USD 1.76 0.06 3.53% |
Director
Mr. James R. Jones is Independent Director of Cumberland Pharmaceuticals Inc. Mr. Jones 35 year career in professional accounting at KPMG LLP included the role of Managing Partner at their Nashville, Tennessee office from 1999 to 2006. He served in various capacities during his career at KPMG which also included positions at their offices in Jackson, Mississippi, Washington, DC and Greenville, South Carolina. During his tenure with KPMG, Mr. Jones led a team of more than 100 individuals providing accounting services for an client base. Following retirement in 2006, he has served as an advisor and provided various consulting services to several companies, including acting as liaison between management and the board of directors of a longterm care facility and serving as interim CEO of a charitable organization. He is currently a board director and member of the audit committee of Argent Trust Company of Tennessee since 2010.
| Age | 67 |
| Tenure | 14 years |
| Professional Marks | MBA |
| Address | 1600 West End Avenue, Nashville, TN, United States, 37203 |
| Phone | 615 255 0068 |
| Web | https://www.cumberlandpharma.com |
Latest Insider Transactions
Jones holds a B.S. from Mississippi College and an M.B.A. from Mississippi State University.James Jones Latest Insider Activity
Tracking and analyzing the buying and selling activities of James Jones against Cumberland Pharmaceuticals stock is an integral part of due diligence when investing in Cumberland Pharmaceuticals. James Jones insider activity provides valuable insight into whether Cumberland Pharmaceuticals is net buyers or sellers over its current business cycle. Note, Cumberland Pharmaceuticals insiders must abide by specific rules, including filing SEC forms every time they buy or sell Cumberland Pharmaceuticals'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
James Jones over a month ago Disposition of 54900 shares by James Jones of NMI Holdings at 30.1586 subject to Rule 16b-3 |
Cumberland Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.0444) % which means that it has lost $0.0444 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.1941) %, meaning that it created substantial loss on money invested by shareholders. Cumberland Pharmaceuticals' management efficiency ratios could be used to measure how well Cumberland Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to rise to -0.1 in 2024. Return On Capital Employed is likely to rise to -0.11 in 2024. At this time, Cumberland Pharmaceuticals' Total Assets are fairly stable compared to the past year. Total Current Assets is likely to rise to about 60.5 M in 2024, whereas Non Current Assets Total are likely to drop slightly above 27.5 M in 2024.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Itzhak Krinsky | Kamada | 65 | |
| YiChung Chao | Regencell Bioscience Holdings | 60 | |
| Stephen Kaplan | Regencell Bioscience Holdings | 57 | |
| Gwen Melincoff | Kamada | 64 | |
| Asaf Frumerman | Kamada | N/A | |
| Charles Brymer | Regencell Bioscience Holdings | 56 | |
| Mary Szela | Alimera Sciences | 55 | |
| Meredith Kaya | Ironwood Pharmaceuticals | N/A | |
| Shmuel Rubinstein | Kamada | 78 | |
| Ken Widder | Evoke Pharma | 65 | |
| Edward Kay | Eagle Pharmaceuticals | N/A | |
| Sean Keenan | Regencell Bioscience Holdings | 41 | |
| Sander Flaum | Eagle Pharmaceuticals | 81 | |
| Jon Duane | Ironwood Pharmaceuticals | 59 | |
| Brian Halak | Alimera Sciences | 45 | |
| Catherine Moukheibir | Ironwood Pharmaceuticals | 58 | |
| Andrew Dreyfus | Ironwood Pharmaceuticals | 59 | |
| Edward Owens | Ironwood Pharmaceuticals | 71 | |
| Tuvia Shoham | Kamada | 70 | |
| Heung Tsui | China Pharma Holdings | 56 | |
| David Keyte | Regencell Bioscience Holdings | 59 | |
Management Performance
| Return On Equity | -0.19 | ||||
| Return On Asset | -0.0444 |
Cumberland Pharmaceuticals Leadership Team
Elected by the shareholders, the Cumberland Pharmaceuticals' board of directors comprises two types of representatives: Cumberland Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Cumberland. The board's role is to monitor Cumberland Pharmaceuticals' management team and ensure that shareholders' interests are well served. Cumberland Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Cumberland Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| John Hamm, Chief Officer | ||
| James Jones, Independent Director | ||
| Kenneth Krogulski, Independent Director | ||
| Caroline Young, Independent Director | ||
| Martin Cearnal, Chief Commercial Officer, Sr. VP and Director | ||
| Adam Mostafa, Managing Director | ||
| Michael Bonner, Senior Director Finance and Accounting and CFO | ||
| Thomas Lawrence, Independent Director | ||
| Jean Marstiller, Senior Secretary | ||
| Chris Bitterman, Vice Marketing | ||
| Joey Jacobs, Independent Director | ||
| A MBA, Chairman, Founder | ||
| Amy Rock, Vice President - Regulatory & Scientific Affairs | ||
| Cindy Patton, Director Marketing | ||
| Gordon Bernard, Director | ||
| Todd Anthony, Vice Development | ||
| James Herman, Chief Compliance Officer and VP of National Accounts | ||
| Leo Pavliv, Senior Vice President - Operations, Chief Development Officer | ||
| Joseph Galante, Independent Director | ||
| Erin Gull, Senior Associate | ||
| Jonathan Griggs, Independent Director | ||
| A Kazimi, Chairman of the Board, CEO |
Cumberland Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Cumberland Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.19 | ||||
| Return On Asset | -0.0444 | ||||
| Profit Margin | (0.16) % | ||||
| Operating Margin | (0.30) % | ||||
| Current Valuation | 22.59 M | ||||
| Shares Outstanding | 14.18 M | ||||
| Shares Owned By Insiders | 44.05 % | ||||
| Shares Owned By Institutions | 15.56 % | ||||
| Number Of Shares Shorted | 17.31 K | ||||
| Price To Earning | (16.05) X |
Pair Trading with Cumberland Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Cumberland Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cumberland Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving against Cumberland Stock
| 0.81 | RZLT | Rezolute Financial Report 9th of May 2024 | PairCorr |
| 0.78 | SNDL | SNDL Inc Financial Report 20th of May 2024 | PairCorr |
| 0.75 | CGC | Canopy Growth Corp Financial Report 27th of June 2024 | PairCorr |
| 0.74 | ACB | Aurora Cannabis Sell-off Trend | PairCorr |
| 0.74 | RVMD | Revolution Medicines Financial Report 13th of May 2024 | PairCorr |
The ability to find closely correlated positions to Cumberland Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Cumberland Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Cumberland Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Cumberland Pharmaceuticals to buy it.
The correlation of Cumberland Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Cumberland Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Cumberland Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Cumberland Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cumberland Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product. For more information on how to buy Cumberland Stock please use our How to Invest in Cumberland Pharmaceuticals guide.You can also try the Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.
Complementary Tools for Cumberland Stock analysis
When running Cumberland Pharmaceuticals' price analysis, check to measure Cumberland Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cumberland Pharmaceuticals is operating at the current time. Most of Cumberland Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Cumberland Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cumberland Pharmaceuticals' price. Additionally, you may evaluate how the addition of Cumberland Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital |
Is Cumberland Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cumberland Pharmaceuticals. If investors know Cumberland will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cumberland Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.44) | Revenue Per Share 2.766 | Quarterly Revenue Growth 0.025 | Return On Assets (0.04) | Return On Equity (0.19) |
The market value of Cumberland Pharmaceuticals is measured differently than its book value, which is the value of Cumberland that is recorded on the company's balance sheet. Investors also form their own opinion of Cumberland Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Cumberland Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cumberland Pharmaceuticals' market value can be influenced by many factors that don't directly affect Cumberland Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cumberland Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cumberland Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cumberland Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.